DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “outperform” rating reiterated by equities researchers at BMO Capital Markets in a note issued to investors on Thursday.

Other analysts have also issued reports about the company. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Robert W. Baird reissued a “hold” rating and set a $79.00 price objective on shares of DexCom in a report on Sunday, September 10th. Barclays PLC started coverage on DexCom in a report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price objective for the company. Canaccord Genuity reissued a “buy” rating and set a $90.00 price objective on shares of DexCom in a report on Wednesday, June 7th. Finally, BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. DexCom has a consensus rating of “Buy” and an average price target of $75.14.

DexCom (DXCM) traded up 7.669% on Thursday, reaching $48.925. The company’s stock had a trading volume of 9,357,971 shares. DexCom has a 52-week low of $45.61 and a 52-week high of $94.24. The firm’s 50-day moving average price is $72.62 and its 200 day moving average price is $73.86. The company’s market cap is $4.23 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same period in the prior year, the business earned ($0.24) EPS. The firm’s revenue for the quarter was up 24.3% on a year-over-year basis. Equities analysts anticipate that DexCom will post ($0.79) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/dexcom-inc-dxcm-stock-rating-reaffirmed-by-bmo-capital-markets-2/1598830.html.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $71.86, for a total transaction of $431,160.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $69.47, for a total value of $100,731.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,223 shares of company stock valued at $2,285,138. 1.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Independent Portfolio Consultants Inc. grew its holdings in DexCom by 0.4% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after purchasing an additional 9 shares during the period. Bbva Compass Bancshares Inc. grew its holdings in DexCom by 1.9% during the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock valued at $268,000 after purchasing an additional 69 shares during the period. Public Employees Retirement Association of Colorado grew its holdings in DexCom by 0.4% during the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock valued at $1,362,000 after purchasing an additional 83 shares during the period. King Luther Capital Management Corp grew its holdings in DexCom by 0.7% during the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock valued at $1,026,000 after purchasing an additional 90 shares during the period. Finally, World Asset Management Inc grew its holdings in DexCom by 4.1% during the second quarter. World Asset Management Inc now owns 3,901 shares of the medical device company’s stock valued at $285,000 after purchasing an additional 155 shares during the period.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.